These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
264 related articles for article (PubMed ID: 15996946)
41. APEX (Assessment of Proteasome inhibition for Extending remissions) trial: phase III randomized, multicenter, placebo-controlled trial to evaluate the efficacy and safety of bortezomib versus dexamethasone in patients with recurrent or treatment-resistant multiple myeloma. Clin Adv Hematol Oncol; 2003 Mar; 1(3):190. PubMed ID: 16235416 [No Abstract] [Full Text] [Related]
42. Bortezomib, thalidomide, and dexamethasone for relapsed multiple myeloma: add it up and wait. Badros A; Gahres N Clin Adv Hematol Oncol; 2005 Dec; 3(12):916-7; discussion 918. PubMed ID: 16555432 [No Abstract] [Full Text] [Related]
43. Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study. Lee SJ; Richardson PG; Sonneveld P; Schuster MW; Irwin D; San Miguel JF; Crawford B; Massaro J; Dhawan R; Gupta S; Anderson KC Br J Haematol; 2008 Nov; 143(4):511-9. PubMed ID: 18986387 [TBL] [Abstract][Full Text] [Related]
44. Bortezomib in multiple myeloma. Mateos MV; San Miguel JF Best Pract Res Clin Haematol; 2007 Dec; 20(4):701-15. PubMed ID: 18070714 [TBL] [Abstract][Full Text] [Related]
47. Proteasome inhibition for treatment of multiple myeloma: clinical update. Stadtmauer EA J Natl Compr Canc Netw; 2004 Nov; 2 Suppl 4():S10-5. PubMed ID: 19795531 [TBL] [Abstract][Full Text] [Related]
48. Extended follow-up of outcome measures in multiple myeloma patients treated on a phase I study with bortezomib and pegylated liposomal doxorubicin. Biehn SE; Moore DT; Voorhees PM; Garcia RA; Lehman MJ; Dees EC; Orlowski RZ Ann Hematol; 2007 Mar; 86(3):211-6. PubMed ID: 17146676 [TBL] [Abstract][Full Text] [Related]
49. Acyclovir to prevent reactivation of varicella zoster virus (herpes zoster) in multiple myeloma patients receiving bortezomib therapy. Vickrey E; Allen S; Mehta J; Singhal S Cancer; 2009 Jan; 115(1):229-32. PubMed ID: 19090004 [TBL] [Abstract][Full Text] [Related]
50. Clinical impact of bortezomib in frontline regimens for patients with multiple myeloma. Manochakian R; Miller KC; Chanan-Khan AA Oncologist; 2007 Aug; 12(8):978-90. PubMed ID: 17766658 [TBL] [Abstract][Full Text] [Related]
51. Approval summary for bortezomib for injection in the treatment of multiple myeloma. Bross PF; Kane R; Farrell AT; Abraham S; Benson K; Brower ME; Bradley S; Gobburu JV; Goheer A; Lee SL; Leighton J; Liang CY; Lostritto RT; McGuinn WD; Morse DE; Rahman A; Rosario LA; Verbois SL; Williams G; Wang YC; Pazdur R Clin Cancer Res; 2004 Jun; 10(12 Pt 1):3954-64. PubMed ID: 15217925 [No Abstract] [Full Text] [Related]
52. [Safety evaluation of bortezomib in multiple myeloma patients with severe renal failure]. Muta T; Nakanishi H; Yasunaga M; Senba S; Murakami H; Kan S; Ueda Y; Fujisaki T Gan To Kagaku Ryoho; 2011 Feb; 38(2):237-41. PubMed ID: 21368487 [TBL] [Abstract][Full Text] [Related]
53. Concurrent radiation therapy and bortezomib in myeloma patient. Berges O; Decaudin D; Servois V; Kirova YM Radiother Oncol; 2008 Feb; 86(2):290-2. PubMed ID: 18199515 [No Abstract] [Full Text] [Related]
56. [Effects of bortezomib at different doses in combination with dexamethasone in treatment of relapsed or refractory multiple myeloma: a comparative study]. Bao L; Lu XJ; Zhang XH; Huang XJ Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(26):1829-31. PubMed ID: 19040018 [TBL] [Abstract][Full Text] [Related]
57. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. Berenson JR; Yang HH; Sadler K; Jarutirasarn SG; Vescio RA; Mapes R; Purner M; Lee SP; Wilson J; Morrison B; Adams J; Schenkein D; Swift R J Clin Oncol; 2006 Feb; 24(6):937-44. PubMed ID: 16418495 [TBL] [Abstract][Full Text] [Related]
58. Impact of cytogenetics in patients with relapsed or refractory multiple myeloma treated with bortezomib: Adverse effect of 1q21 gains. Chang H; Trieu Y; Qi X; Jiang NN; Xu W; Reece D Leuk Res; 2011 Jan; 35(1):95-8. PubMed ID: 20537706 [TBL] [Abstract][Full Text] [Related]
59. Cost effectiveness of bortezomib in the treatment of advanced multiple myeloma. Mehta J; Duff SB; Gupta S Manag Care Interface; 2004 Sep; 17(9):52-61. PubMed ID: 15521286 [TBL] [Abstract][Full Text] [Related]
60. Sustained remission including marked regression of a paravertebral plasmacytoma in a patient with heavily pretreated, relapsed multiple myeloma after treatment with bortezomib. Krauth MT; Bankier A; Valent P; Kalhs P; Drach J Leuk Res; 2005 Dec; 29(12):1473-7. PubMed ID: 15964068 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]